Abstract:Objective: To investigate the involvement of posterior auricular muscle (PAM) and the effect of botulinum toxin type A (BTX-A) injection into PAM in patients with hemifacial spasm (HFS) complicated with auricular symptoms. Methods: Sixty-three consecutive HFS patients complicated with auricular symptoms such as tinnitus or murmur, "ticking" or a "clicking" sound and discomfort on the same side, who were referred to our department between July 2009 and January 2010, were enrolled. The diagnosis of idiopathic HFS was made clinically. The patients were largely randomized into two BTX-A treatment groups according to the order of referral. The first group included 33 cases where the injection sites were routinely located at the frontal, orbicularis oculi, zygomaticus and buccinator muscles while the other was the PAM group, which included 30 cases, where 4 units of BTX-A were additionally injected into the PAM prior to injection at other sites. A test of blink reflex was performed and the lateral spread of blink reflex to the orbicularis oris (OO) and PAM, i.e. abnormal muscle response (AMR), was recorded and the peak-peak amplitude of AMR was measured. The patients were followed up clinically and electrophysiologically for at least 4 weeks (29.47 +/- 2.53 days). Results: 1) Before injection, the latencies of R1, R2, R2' were normal, there was no significant difference between uninjured and affected side; The amplitudes of R1, R2, R2' in affected side were higher. 2) After injection, there was no significant change of the R1, R2 and R2' latencies; The amplitudes of R1, R2 and R2' decreased significantly. 3) Patients reported that their auricular symptoms subsided after injection in both groups; The remission rate was 45.5% (15/33) and 76.7% (23/30) in the regular and PAM group, respectively, with a higher rate in the PAM group (chi(2) = 6.40, P = 0.011). 4) In both groups the AMR amplitude decreased significantly after injection. In the regular group, the respective OO amplitudes (mu V) before and after injection were 304.00 +/- 30.34 and 129.33 +/- 9.59 (t = 5.820, P = 0.000), and for PAM the amplitudes were 298.00 +/- 33.28 and 184.67 +/- 20.21 (t = 2.818, P = 0.014); in the PAM group, the before and after injection OO amplitudes were 405.33 +/- 66.71 and 116.00 +/- 9.99 (t = 4.214, P = 0.001), and for PAM they were 390.00 +/- 53.58 and 72.00 +/- 9.67 (t = 6.011, P = 0.000), respectively. 5) PAM amplitudes in the PAM group decreased more significantly after BTX-A injection compared with those in the regular group (t = 4.237, P = 0.001). Conclusions: The treatment on HFS with local injection of BTX-A is very effective. In HFS complicated with auricular symptoms patients, electrophysiological studies are helpful for guiding treatment plans, and the auricular symptoms could be improved by BTX-A injection into the PAM in addition to the regular injection sites.

Factors influencing short-term prognosis after botulinum toxin type A treatment for hemifacial spasm：A retrospective study

Evaluation of the effect of botulinum toxin A on the physical and mental health of patients with hemifacial spasm

Hemifacial spasm through the last three decades: From etiology to efficacy and safety of long-term botulinum toxin treatment

Clinical Observation of Treatment with Botulinum Toxin A for the Ipsilateral Tinnitus in Hemifaciai Spasm Patients

Clinical and therapeutic features of patients with hemifacial spasm and benign essential blepharospasm

Clinical Effectiveness of Ultrasound Guided Subacromial-Subdeltoid Bursa Injection of Botulinum Toxin Type A in Hemiplegic Shoulder Pain A Retrospective Cohort Study

Exploration of Effect and Dosage of Botulinum Toxin Type A for Long-Term Treatment of Idiopathic Blepharospasm

Therapeutic effects of botulinum toxin A in patients with hemifacial spasm or blepharospasm

[The Effect of Botulinum A Toxin Repeated Injection in Treating Blepharospasm and Hemifacial Spasm].

[Botulinum Toxin Treatment for Hemifacial Spasm:Based on the Practical Clinical Experience in the Neurology Outpatient Clinic]

Increasing the area and varying the dosage of Botulinum toxin a injections for effective treatment of hemifacial spasm

Clinical features and treatment status of hemifacial spasm in China

Botulinum Toxin Relieves Anxiety and Depression in Patients with Hemifacial Spasm and Blepharospasm.

Clinical analysis of the therapy of facial spasm by small dose of Botulinum toxin type A

Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies

Study of the effect of botulinum toxin on electrophysiological monitoring during microvascular decomp-ression surgery for patients with hemifacial spasm

Clinical and Electrophysiological Studies of Botulinum Toxin Type A to Treat Hemifacial Spasm Complicated with Auricular Symptoms

Subjective assessment of effectiveness, quality of life, and psychological status of patients receiving botulinum toxin therapy for hemifacial spasm, blepharospasm, or cervical dystonia

The influence of long-term repeat BTX injection on the latency and amplitude of facial nerve

Clinical analysis of the treatment of facial spasm by standardized bit point injection of Botulinum toxin A

Two Cases of Hemifacial Spasm Completely Recovered after Repeated BTX-A Treatment